A Study of NIO752 for Progressive Supranuclear Palsy
This study is testing a treatment called NIO752 for people with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS). Researchers want to see if NIO752 is effective and safe. You might be able to join if you are between 41 and 81 years old and have a diagnosis of mild-to-moderate PSP-RS that started less than 5 years ago. The study will measure success by looking at changes in a score called mPSPRS-10 over 72 weeks. This study plans to enroll about 300 participants.
- Study design
- This is a randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either NIO752 or a placebo (an inactive substance), and neither you nor your doctor will know which you are receiving. After this initial period, all participants will have the option to receive NIO752 in an open-label extension.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at Week 72, and participants may continue with NIO752 treatment in an open-label extension after this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
At a glance
Conditions
Where it's being run
42 sites across 21 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in the mPSPRS-10 scoreBaseline, Week 72
The 10-item Progressive Supranuclear Palsy Rating Scale (mPSPRS-10) is a modified version of the original 28 item PSPRS developed to improve clinical meaningfulness and statistical performance. The 10 items measure three key motor domains: gait, limb function, and bulbar. The mPSPRS-10 ranges between 0 and 30, with higher scores indicating greater disability.